e.g. mhealth
Search Results (1 to 6 of 6 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Medical Informatics
- 2 Journal of Medical Internet Research
- 1 Interactive Journal of Medical Research
- 1 JMIR Infodemiology
- 0 Medicine 2.0
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
(3) On April 5, 2020, the president of the United States promoted the use of hydroxychloroquine for COVID-19 [27]. (4) Then the Center for Disease Control deleted a report of physicians using hydroxychloroquine [3]. (5) The Food and Drug Administration on April 24, 2020, announced to use hydroxychloroquine with caution outside of the hospital or clinical trial secondary to arrhythmias [28]. (6) On May 18, 2020, the president of the United States reported tweets that he is taking hydroxychloroquine to protect
JMIR Infodemiology 2024;4:e56675
Download Citation: END BibTex RIS
Hydroxychloroquine (HCQ) is among the most commonly used medications for patients with autoimmune conditions and received special attention in 2020 as a potential treatment for COVID-19, resulting in drug shortages for chronic users [1]. These drug shortages, combined with recent guidelines emphasizing toxicities associated with long-term use, highlighted the issue of prescribing HCQ in appropriate doses. Long-term use of HCQ, especially at higher doses, can cause severe retinal toxicity in some patients.
JMIR Med Inform 2023;11:e44455
Download Citation: END BibTex RIS
Antimalaria drug hydroxychloroquine, which is one of the most talked-about drugs for treating COVID-19, was also found in our mining, albeit with a negative interaction. Our model found it is a negative (ie, ineffective) drug with 64.67% confidence. Additionally, it also revealed that this drug has 111 side effects including anemia, hemorrhage, liver disorder, hepatitis fulminant, cardiomyopathy, and cardiac failure, which makes it a risky option, especially for patients with heart and liver complications.
JMIR Med Inform 2020;8(11):e21648
Download Citation: END BibTex RIS
Among others, hydroxychloroquine (HCQ) and the interleukin-6 (IL-6) inhibitor, tocilizumab (TCZ), became popular options to treat COVID-19. There is no concrete evidence supporting their use, and they were widely adopted across the world based on anecdotal data. Our hospital, following the guidelines of its parent enterprise, permitted the use of HCQ in COVID-19 patients who had respiratory insufficiency as indicated by low oxygen saturation.
J Med Internet Res 2020;22(9):e21758
Download Citation: END BibTex RIS
Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine
Hydroxychloroquine has been available since the 1950s [6] and has been used to treat malaria, lupus erythematosus, and rheumatoid arthritis. Most recently, hydroxychloroquine has been highlighted as a potential intervention to support patients with coronavirus disease (COVID-19). Although the efficacy outcomes of hydroxychloroquine are different in each clinical condition for which it is used, adverse events tend to be consistent.
J Med Internet Res 2020;22(8):e20007
Download Citation: END BibTex RIS
Hydroxychloroquine (HCQ), a chemotherapeutic drug, inhibits the erythrocytic forms of malarial parasites with antiautophagic and immunosuppressive activities. Its main mechanism of action is inhibition of plasmodial heme polymerase [1]. HCQ, mostly used as an antimalarial drug, has been used for the management of inflammatory skin conditions for more than 50 years [2].
Interact J Med Res 2019;8(4):e15218
Download Citation: END BibTex RIS